Ryan Haumschild, PharmD, MS, MBA

What is optimal timing for starting immunotherapy in patients with small cell lung cancer (SCLC)? What are the considerations when deciding on whether to administer immunotherapy in the inpatient or outpatient setting? What are barriers to diagnosing and treating SCLC […]

Opinion Video October 18, 2024 Key Takeaways Financial constraints and limited healthcare access are significant barriers to timely lupus nephritis treatment, affecting patient outcomes. Patient assistance programs, educational initiatives, and support groups are crucial resources for facilitating access to lupus

Opinion Video October 18, 2024 Panelists discuss the differences in efficacy and safety profiles between belimumab and voclosporin for lupus nephritis (LN) and how payers are evaluating their value, including considerations of cost-effectiveness in LN management. How do you monitor

What are best practices for working with payers to ensure that patients with small cell lung cancer (SCLC) get access to the necessary medications? How do you educate patients about SCLC, and which resources do you find useful in sharing

What is the role of biomarker testing in your patients with small cell lung cancer (SCLC)? When in their treatment journey do you incorporate it? What are the current unmet needs with biomarker testing in SCLC, and how can they

Panelists discuss the considerations guiding treatment choices for lupus nephritis, such as drug interactions, patient characteristics, and steroid use, and how treatment approaches might differ between nephrologists and rheumatologists. Source link Ryan Haumschild, PharmD, MS, MBA

What is your perspective on the differences between the efficacy and safety profiles of belimumab and voclosporin in the treatment of lupus nephritis (LN)? (Dr. Larranaga and Dr. Wells) How are payers evaluating the value of belimumab and voclosporin in

Now that we’ve discussed extensive-stage small cell lung cancer (SCLC), let’s move into limited stage. Durvalumab has also demonstrated encouraging results in patients with limited-stage SCLC in the ADRIATIC trial. Can you discuss the trial design and the key results

Panelists discuss how atezolizumab is being investigated in the NRG-LU005 trial for limited-stage small cell lung cancer (SCLC), comparing its trial design with that of the ADRIATIC study, while also exploring the potential benefits of using a single immunotherapy across

Video content above is prompted by the following: To set the stage, what are some of the psychological and emotional aspects of treatment decision-making with patients entering the third-line stage of metastatic colorectal cancer? What are your recommendations for involving